|
|
|
|
|
Troglitazone
drug data and news
Troglitazone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Troglitazone | ||
| Brand Names/Synonyms | Romglizone; Rezulin; Troglitazone [USAN:BAN:INN]; Prelay; Noscal; Mesylate | ||
| Indication | For the treatment of Type II diabetes mellitus | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Troglitazone is an oral antihyperglycemic agent which acts primarily by decreasing insulin resistance. Troglitazone is used in the management of type II diabetes (noninsulin-dependent diabetes mellitus (NIDDM) also known as adult-onset diabetes). It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. Troglitazone is not chemically or functionally related to either the sulfonylureas, the biguanides, or the g-glucosidase inhibitors. Troglitazone may be used concomitantly with a sulfonylurea or insulin to improve glycemic control. | ||
| Mechanism Of Action | Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulindependent glucose disposal in skeletal muscle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that regulate the transcription of a number of insulin responsive genes critical for the control of glucose and lipid metabolism. Unlike sulfonylureas, troglitazone is not an insulin secretagogue. | ||
| Troglitazone News (When available) |
| ||
| Dosage Forms | Not Available | ||
| Drug_Category | Vasodilator Agents; Hypoglycemic Agents; Platelet Aggregation Inhibitors; Fibrinolytic Agents; Antineoplastic Agents; ATC:A10BG01 | ||
| Absorption | Absorbed rapidly. Food increases the extent of absorption by 30% to 85%. | ||
| Interactions | Interactions for Troglitazone: Oral Contraceptives: Administration of Troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30% which could result in loss of contraception. Therefore, a higher dose of oral contraceptive or an alternative method of contraception should be considered. Terfenadine: Coadministration of Troglitazone with terfenadine decreases the plasma concentration of both terfenadine and its active metabolite by 50-70% and may result in decreased efficacy of terfenadine. Cholestyramine: Concomitant administration of cholestyramine with Troglitazone reduces the absorption of troglitazone by 70%; thus, coadministration of cholestyramine and Troglitazone is not recommended. Glyburide: Coadministration of Troglitazone and glyburide does not appear to alter troglitazone or glyburide pharmacokinetics. Digoxin: Coadministratjon of Troglitazone with digoxin does not alter the steady-state pharmacokinetics of digoxin. Warfarin: Troglitazone has no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin therapy. Acetaminophen: Coadministration of acetaminophen and Troglitazone does not alter the pharmacokinetics of either drug. Metformin: No information is available on the use of Troglitazone with metformin. Ethanol: A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in Troglitazone-treated patients with type II diabetes mellitus. The above interactions with terfenadine and oral contraceptives suggest that troglitazone may induce drug metabolism by CYP3A4. Studies have not been performed with other drugs metabolized by this enzyme such as: astemizole, calcium channel blockers, cisapride, corticosteroids cyclosporine. HMG-CoA reductase inhibitors, tacrolimus, triazolam, and trimetrexate. The possi bility of altered safety and efficacy should be considered when Troglitazone is used concomitantly with these drugs. Patients stable on one or more of these agents when Troglitazone is started should be closely monitored and their therapy adjusted as necessary. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)methoxy]phenyl]methyl]thiazolidine-2,4-dione | ||
| Chemical Formula | C24H27NO5S | ||
| Molecular Weight | 441.541 g/mol | ||
| Smiles String | CC1=C(C(=C2CCC(OC2=C1C)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)O | ||
| Melting Point | 184-186 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 16-34 hours | ||
| Protein Binding [%] | > 99% (to Serum albumin) | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Troglitazone.html http://www.rxlist.com/cgi/generic/troglitazone.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00488 | ||
| CAS Registry Number | 97322-87-7 | ||
| KEGG Compound ID | C07181 | ||
| PubChem ID | SID:194350 | ||
| PharmGKB ID | PA451799 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |